The vaccine for human papillomavirus got a bad rap when it debuted. And yet time has shown it's very effective in reducing cancers linked to HPV.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
Sept. 26, 2019: Racial disparities in the PrEP continuum; HIV and ocular syphilis; Kaposi sarcoma among people with well-suppressed HIV; modifiable risk factors in the management of chronic kidney disease.
A new study adds to mounting evidence that all people should be screened and offered the vaccine for human papillomavirus.
Experts Flummoxed By Conflicting New Data on STIs, HIV, and Long-Term Contraception in Sub-Saharan Africa
ECHO trial results and follow-up studies find unexpectedly low rates of some STIs among users of certain long-term hormonal contraceptives. They also find high HIV rates (unrelated to the contraceptives) that suggest considerable value for PrEP integration.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
June 27, 2019: Long-term viability of NRTI-free salvage therapy; factors associated with HIV treatment interruption; evolution of frailty risk among older people; skin and soft tissue infections among people with HIV.
Rectal and throat tests matter too, and providers should be recommending them.
These two tests make it easier to diagnose sexually transmitted infections that often go untreated.
May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.